Novavax Investor Relations

Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season

08/28/2026

COVID-19 remains a public health challenge, particularly among older adults and high-risk populations1 Novavax's partners are ready to bring its protein-based, non-mRNA vaccine with a favorable...

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

08/06/2026

Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework Improved GAAP Combined R&D and SG&A expense guidance by $10 million at mid-point...

Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026

07/30/2026

Novavax, Inc. (Nasdaq: NVAX) today announced that the Company plans to release its second quarter 2026 financial results before the open of the U.S. financial markets on Thursday, August 6, 2026....

Novavax to Participate in 2026 Jefferies Global Healthcare Conference

06/01/2026

Novavax, Inc. (Nasdaq: NVAX) today announced it will participate in the 2026 Jefferies Global Healthcare Conference. Conference Details: Fireside Chat Date: Thursday, June 4, 2026 Time: 10:30 –...

Novavax to Participate in BofA Securities 2026 Health Care Conference

05/07/2026

Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2026 Health Care Conference. Conference Details: Fireside Chat Date: Wednesday, May 13, 2026 Time: 3:00...